Exicure (NASDAQ:XCUR) Posts Quarterly Earnings Results, Beats Expectations By $18.31 EPS

Exicure (NASDAQ:XCUR) released its quarterly earnings data on Friday. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($18.60) by $18.31, FiscalAI reports.

Exicure Price Performance

NASDAQ XCUR opened at $3.19 on Friday. Exicure has a 12 month low of $2.63 and a 12 month high of $10.80. The company has a market capitalization of $20.32 million, a price-to-earnings ratio of -4.14 and a beta of 3.62. The company’s fifty day moving average price is $3.64 and its two-hundred day moving average price is $4.41.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded shares of Exicure from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

About Exicure

Exicure is a clinical‐stage biotechnology company pioneering the development of next‐generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology‐based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard‐to‐reach tissues such as the central nervous system.

The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology.